The Goldman Sachs Group Cuts uniQure (NASDAQ:QURE) Price Target to $9.00

uniQure (NASDAQ:QURE) had its price objective cut by The Goldman Sachs Group from $37.00 to $9.00 in a research report released on Tuesday morning,Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock.

QURE has been the topic of a number of other reports. Royal Bank Of Canada cut uniQure from a “moderate buy” rating to a “hold” rating and set a $11.00 price target on the stock. in a research note on Monday. Stifel Nicolaus set a $14.00 price objective on uniQure in a report on Monday. TD Cowen restated a “buy” rating on shares of uniQure in a research note on Tuesday. Wells Fargo & Company reaffirmed an “equal weight” rating and issued a $15.00 price target (down from $60.00) on shares of uniQure in a report on Tuesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $34.33.

uniQure Stock Up 17.8%

Shares of NASDAQ:QURE opened at $10.65 on Tuesday. uniQure has a fifty-two week low of $7.76 and a fifty-two week high of $71.50. The firm’s 50 day moving average price is $22.25 and its 200 day moving average price is $29.44. The company has a quick ratio of 7.12, a current ratio of 10.43 and a debt-to-equity ratio of 0.25. The stock has a market cap of $665.94 million, a price-to-earnings ratio of -3.09 and a beta of 0.73.

uniQure (NASDAQ:QURE) last announced its quarterly earnings data on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.37. The company had revenue of $5.57 million for the quarter, compared to the consensus estimate of $4.84 million. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. As a group, equities research analysts predict that uniQure will post -3.75 earnings per share for the current fiscal year.

Insider Transactions at uniQure

In related news, CFO Christian Klemt sold 6,217 shares of the company’s stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $23.86, for a total value of $148,337.62. Following the completion of the sale, the chief financial officer owned 211,513 shares in the company, valued at $5,046,700.18. This represents a 2.86% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Matthew C. Kapusta sold 12,378 shares of the stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $23.86, for a total transaction of $295,339.08. Following the sale, the chief executive officer owned 639,076 shares of the company’s stock, valued at approximately $15,248,353.36. This represents a 1.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 50,598 shares of company stock worth $1,248,588 in the last three months. Corporate insiders own 4.79% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Jefferies Financial Group Inc. acquired a new stake in shares of uniQure during the second quarter worth about $29,217,000. State Street Corp raised its stake in uniQure by 123.8% during the 4th quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. lifted its position in uniQure by 155.3% during the 4th quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after acquiring an additional 1,785,275 shares during the period. Avoro Capital Advisors LLC grew its stake in shares of uniQure by 38.4% in the 4th quarter. Avoro Capital Advisors LLC now owns 6,150,000 shares of the biotechnology company’s stock valued at $147,170,000 after purchasing an additional 1,705,556 shares during the last quarter. Finally, MPM Bioimpact LLC acquired a new position in shares of uniQure in the fourth quarter valued at approximately $33,062,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Short-term technical/bounce dynamics — commentators note QURE has been deeply oversold and could see a trend reversal as buyers step in on low prices; that dynamic can fuel sharp intraday gains. uniQure (QURE) Loses 67.5% in 4 Weeks
• Positive Sentiment: Elevated trading after recent earnings — coverage notes unusually high volume following uniQure’s recent quarter (the company beat the EPS view), which can amplify swings and supports short-term buyers. uniQure Sees Unusually-High Trading Volume Following Strong Earnings
• Neutral Sentiment: Mixed analyst coverage — some firms (e.g., Mizuho) have issued neutral/hold-type ratings, reflecting uncertainty; this keeps the stock range-bound until regulatory clarity arrives. uniQure Earns Neutral Rating from Mizuho
• Neutral Sentiment: Broker notes and price-target moves are active — these updates increase day-to-day volatility but are secondary to FDA / clinical outcomes for long-term valuation. uniQure Receives Equal Weight Rating from Wells Fargo
• Negative Sentiment: Regulatory risk: senior FDA and HHS officials publicly criticized uniQure’s Huntington’s gene therapy, called it a “failed” product in media remarks, and said a randomized placebo-controlled study is needed — a development that likely delays any Biologics License Application (BLA) approval path and raises clinical/expense uncertainty. Federal health officials attacked an Amsterdam-based biotech company
• Negative Sentiment: Media and agency follow-ups echo the criticism — Reuters, CNBC and others report the FDA defended its call for a new placebo study and said uniQure’s pivotal data do not prove slowed disease progression, reinforcing downside clinical risk. Sr. FDA official calls Uniqure’s Huntington’s disease treatment a failure
• Negative Sentiment: Legal exposure: multiple law firms have filed or circulated class-action notices alleging securities fraud tied to disclosures about the trial design and timing of filings — this raises potential litigation costs, management distraction and settlement risk. Pomerantz investor alert
• Negative Sentiment: Analyst downgrades and lower targets — several firms cut price targets and sentiment (Wells Fargo, Chardan, others), which can pressure the stock until regulatory clarity and confirmatory data are provided. Chardan Capital Lowers uniQure Price Target

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.